S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
SHOCKING Crypto Leak… (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The #1 Crypto for 2024 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial

Mersana Therapeutics (MRSN) Earnings Date, Estimates & Call Transcripts

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)
Free MRSN Stock Alerts
$3.25
-0.09 (-2.69%)
(As of 04/19/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 28)
-$0.16
Consensus EPS
(Feb. 28)
-$0.16
Read Call Transcript
Listen to Call
Skip Charts & View Estimated and Actual Earnings Data
Earnings Per ShareRevenue

MRSN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

MRSN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Mersana Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242($0.21)($0.13)($0.17)
Q2 20242($0.22)($0.13)($0.18)
Q3 20242($0.22)($0.11)($0.17)
Q4 20242($0.22)($0.10)($0.16)
FY 20248($0.87)($0.47)($0.67)
Q1 20251($0.23)($0.23)($0.23)
Q2 20251($0.19)($0.19)($0.19)
Q3 20251($0.17)($0.17)($0.17)
Q4 20251($0.17)($0.17)($0.17)
FY 20254($0.76)($0.76)($0.76)

MRSN Earnings Date and Information

Mersana Therapeutics last posted its earnings data on February 28th, 2024. The reported ($0.16) EPS for the quarter, hitting analysts' consensus estimates of ($0.16). The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $22.59 million. Its revenue was down 27.1% on a year-over-year basis. Mersana Therapeutics has generated ($1.50) earnings per share over the last year (($1.50) diluted earnings per share). Earnings for Mersana Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.67) per share. Mersana Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Mersana Therapeutics Earnings History by Quarter

Export to Excel
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)		------- 
2/28/2024Q4 2023($0.16)($0.16)-($0.16)$22.59 million$10.70 million    
11/7/2023Q3 2023($0.31)($0.35)($0.04)($0.35)$9.30 million$7.70 million    
8/8/2023Q2 2023($0.44)($0.47)($0.03)($0.47)$12.93 million$10.70 million
5/9/2023Q1 2023($0.41)($0.52)($0.11)($0.52)$18.29 million$7.80 million    
2/28/2023Q4 2022($0.47)($0.44)+$0.03($0.44)$27.85 million$14.69 million
11/7/2022Q3 2022($0.03)($0.61)($0.58)($0.61)$38.57 million$5.57 million
8/8/2022Q2 2022($0.50)($0.55)($0.05)($0.55)$3.18 million$4.28 million
5/9/2022Q1 2022($0.31)($0.59)($0.28)($0.59)$20.01 million$2.04 million    
2/28/2022Q4 2021($0.67)($0.68)($0.01)($0.68)$0.01 million$0.01 million    
11/9/2021Q3 2021($0.58)($0.63)($0.05)($0.63)$0.01 million$0.01 million    
8/6/2021Q2 2021($0.50)($0.59)($0.09)($0.59)-$0.01 million    
5/10/2021Q1 2021($0.39)($0.50)($0.11)($0.50)$0.25 million$0.01 million  

Mersana Therapeutics Earnings - Frequently Asked Questions

When is Mersana Therapeutics's earnings date?

Mersana Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on MRSN's earnings history.

Did Mersana Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Mersana Therapeutics (NASDAQ:MRSN) reported ($0.16) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.16). Learn more on analysts' earnings estimate vs. MRSN's actual earnings.

How can I listen to Mersana Therapeutics's earnings conference call?

The conference call for Mersana Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Mersana Therapeutics's conference call transcript?

The conference call transcript for Mersana Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Mersana Therapeutics generate each year?

Mersana Therapeutics (NASDAQ:MRSN) has a recorded annual revenue of $36.85 million.

How much profit does Mersana Therapeutics generate each year?

Mersana Therapeutics (NASDAQ:MRSN) has a recorded net income of -$171.67 million. MRSN has generated -$1.50 earnings per share over the last four quarters.

What is Mersana Therapeutics's EPS forecast for next year?

Mersana Therapeutics's earnings are expected to decrease from ($0.60) per share to ($0.67) per share in the next year.


More Earnings Resources from MarketBeat

Related Companies:
Earnings Tools:
Earnings By Country:
Latest Articles:
This page (NASDAQ:MRSN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Urgent alert: open this for a huge profit potential
Timothy Sykes